Search results
Showing 1 to 15 of 32 results for interstitial lung disease
Inhaled treprostinil for treating pulmonary hypertension with interstitial lung disease [ID6459]
In development Reference number: GID-TA11572 Expected publication date: 21 May 2026
Idiopathic pulmonary fibrosis in adults: diagnosis and management (CG163)
This guideline covers diagnosing and managing idiopathic pulmonary fibrosis in people aged 18 and over. It aims to improve the quality of life for people with idiopathic pulmonary fibrosis by helping healthcare professionals to diagnose the condition and provide effective symptom management.
This quality standard covers managing idiopathic pulmonary fibrosis (gradual scarring of the lungs) in adults. It includes diagnosis by a multidisciplinary team, managing symptoms and palliative care. It describes high-quality care in priority areas for improvement.
View quality statements for QS79Show all sections
Sections for QS79
- Quality statements
- Quality statement 1: Diagnosis of idiopathic pulmonary fibrosis
- Quality statement 2: Access to a specialist nurse
- Quality statement 3: Assessment for oxygen therapy
- Quality statement 4: Pulmonary rehabilitation
- Quality statement 5: Palliative care
- Update information
- About this quality standard
NICE is unable to make a recommendation on nintedanib (Ofev) for treating fibrosing interstitial lung disease in people 6 to 17 years. This is because the company did not provide an evidence submission.
Show all sections
Sections for TA1111
Nintedanib for treating progressive fibrosing interstitial lung diseases (TA747)
Evidence-based recommendations on nintedanib for treating progressive fibrosing interstitial lung diseases in adults.
Lung texture analysis for measuring interstitial lung diseases (MIB272)
NICE has developed a medtech innovation briefing (MIB) on lung texture analysis for measuring interstitial lung diseases .
Summary of the evidence on rituximab (MabThera) for treating skin involvement in systemic sclerosis to inform local NHS planning and decision-making
Nerandomilast for treating idiopathic pulmonary fibrosis or progressive pulmonary fibrosis [ID6446]
In development Reference number: GID-TA11552 Expected publication date: 09 September 2026
This guideline sets out an antimicrobial prescribing strategy for acute cough associated with an upper respiratory tract infection or acute bronchitis in adults, young people and children. It aims to limit antibiotic use and reduce antibiotic resistance.
Evidence-based recommendations on the early use of digital technologies for applying algorithms to spirometry to support asthma and chronic obstructive pulmonary disease (COPD) diagnosis in primary care and community diagnostic centres.
Nintedanib for treating interstitial lung disease caused by systemic sclerosis [ID1420]
Discontinued Reference number: GID-TA10427
Percutaneous radiofrequency ablation for primary or secondary lung cancers (HTG244)
Evidence-based recommendations on percutaneous radiofrequency ablation for primary or secondary lung cancers. This involves inserting 1 or more electrodes (needle-like probes) through the chest into the lung and using an electrical current to produce heat to destroy the cancer cells.
View recommendations for HTG244Show all sections
Evidence-based recommendations on erlotinib (Tarceva) and gefitinib (Iressa) for treating non-small-cell lung cancer after chemotherapy in adults.
Evidence-based recommendations on nintedanib (Ofev) for treating idiopathic pulmonary fibrosis in adults when forced vital capacity is above 80% predicted.